OBJECTIVE: There is evidence that estrogens and some of their metabolites are involved in endometrial cancer pathogenesis. As estrogens mediate their effects via the estrogen receptors, ESR1 and ESR2, the objective of this investigation was to determine whether six single nucleotide polymorphisms (SNPs) in these two genes were over-represented in a population of endometrial cancer patients compared with a healthy matched control population, thereby associating differences in these genes with endometrial cancer. DESIGN: The study is a case-control investigation large enough to detect a two-fold increased risk, assuming a dominant genetic model, with P = 0.05 and 80% power. SETTING: The study and control populations were all from the Hunter-New England region of New South Wales, Australia collected between the years 1992 and 2005. POPULATION: The study consisted of 191 endometrial cancer patients and 291 healthy controls matched for gender and age. METHODS: Two SNPs in ESR1 and four SNPs in ESR2 were genotyped using PCR-based restriction fragment length polymorphism analysis and real-time PCR. Odds ratios were calculated using unconditional logistic regression and SIMHAP was used for haplotype analysis, adjusting for potential endometrial cancer risk factors. Kaplan-Meier survival analysis, Cox regression and t tests were used to examine the patient's age of diagnosis of endometrial cancer and genotype. MAIN OUTCOME MEASURES: Over-representation of ESR1 and ESR2 polymorphisms in the endometrial cancer population compared with the control population indicates an involvement in the development and/or progression of disease. RESULTS: Two ESR1 (rs2234693 and rs9340799) and two ESR2 (rs1255998 and rs944050) polymorphisms were associated with an increased risk of endometrial cancer. Following adjustment for risk factors, the association with the ESR1 and ESR2 polymorphisms (rs2234693, rs1255998 and rs944050) remained highly significant. Haplotype analysis revealed that carriers of the ESR1 haplotype (variant alleles; rs2234693 and rs9340799) and the ESR2 haplotype (variant allele; rs1255998 and wild-type alleles; rs944050, rs4986938 and rs1256049) were at an increased risk (OR 1.862, P = 0.013 and OR 1.918, P = 0.046 respectively). This risk was even greater in women carrying both risk haplotypes (OR 5.041, P = 0.007). CONCLUSIONS: Our data suggest that the ESR1 (rs2234693 and rs9340799) and the ESR2 (rs1255998 and rs944050) polymorphisms may be associated with an increased risk of developing endometrial cancer.
OBJECTIVE: There is evidence that estrogens and some of their metabolites are involved in endometrial cancer pathogenesis. As estrogens mediate their effects via the estrogen receptors, ESR1 and ESR2, the objective of this investigation was to determine whether six single nucleotide polymorphisms (SNPs) in these two genes were over-represented in a population of endometrial cancerpatients compared with a healthy matched control population, thereby associating differences in these genes with endometrial cancer. DESIGN: The study is a case-control investigation large enough to detect a two-fold increased risk, assuming a dominant genetic model, with P = 0.05 and 80% power. SETTING: The study and control populations were all from the Hunter-New England region of New South Wales, Australia collected between the years 1992 and 2005. POPULATION: The study consisted of 191 endometrial cancerpatients and 291 healthy controls matched for gender and age. METHODS: Two SNPs in ESR1 and four SNPs in ESR2 were genotyped using PCR-based restriction fragment length polymorphism analysis and real-time PCR. Odds ratios were calculated using unconditional logistic regression and SIMHAP was used for haplotype analysis, adjusting for potential endometrial cancer risk factors. Kaplan-Meier survival analysis, Cox regression and t tests were used to examine the patient's age of diagnosis of endometrial cancer and genotype. MAIN OUTCOME MEASURES: Over-representation of ESR1 and ESR2 polymorphisms in the endometrial cancer population compared with the control population indicates an involvement in the development and/or progression of disease. RESULTS: Two ESR1 (rs2234693 and rs9340799) and two ESR2 (rs1255998 and rs944050) polymorphisms were associated with an increased risk of endometrial cancer. Following adjustment for risk factors, the association with the ESR1 and ESR2 polymorphisms (rs2234693, rs1255998 and rs944050) remained highly significant. Haplotype analysis revealed that carriers of the ESR1 haplotype (variant alleles; rs2234693 and rs9340799) and the ESR2 haplotype (variant allele; rs1255998 and wild-type alleles; rs944050, rs4986938 and rs1256049) were at an increased risk (OR 1.862, P = 0.013 and OR 1.918, P = 0.046 respectively). This risk was even greater in women carrying both risk haplotypes (OR 5.041, P = 0.007). CONCLUSIONS: Our data suggest that the ESR1 (rs2234693 and rs9340799) and the ESR2 (rs1255998 and rs944050) polymorphisms may be associated with an increased risk of developing endometrial cancer.
Authors: Zhi-Jun Dai; Bao-Feng Wang; Yun-Feng Ma; Hua-Feng Kang; Yan Diao; Yang Zhao; Shuai Lin; Ye Lv; Meng Wang; Xi-Jing Wang Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Eva Lundin; Isaac Wirgin; Annekatrin Lukanova; Yelena Afanasyeva; Vittorio Krogh; Tomas Axelsson; Kari Hemminki; Tess V Clendenen; Alan A Arslan; Nina Ohlson; Sabina Sieri; Nirmal Roy; Karen L Koenig; Annika Idahl; Franco Berrino; Paolo Toniolo; Göran Hallmans; Asta Försti; Paola Muti; Per Lenner; Roy E Shore; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Date: 2012-05-25 Impact factor: 2.984
Authors: Santosh Philips; Alexandra Richter; Steffi Oesterreich; James M Rae; David A Flockhart; Narayanan B Perumal; Todd C Skaar Journal: Horm Cancer Date: 2012-04 Impact factor: 3.869
Authors: Pedram Razavi; Eunjung Lee; Leslie Bernstein; David Van Den Berg; Pamela L Horn-Ross; Giske Ursin Journal: Int J Cancer Date: 2011-08-17 Impact factor: 7.396
Authors: Hannah P Yang; Jesus Gonzalez Bosquet; Qizhai Li; Elizabeth A Platz; Louise A Brinton; Mark E Sherman; James V Lacey; Mia M Gaudet; Laurie A Burdette; Jonine D Figueroa; Julia G Ciampa; Jolanta Lissowska; Beata Peplonska; Stephen J Chanock; Montserrat Garcia-Closas Journal: Carcinogenesis Date: 2010-01-06 Impact factor: 4.944
Authors: Tracy A O'Mara; Dylan M Glubb; Jodie N Painter; Timothy Cheng; Joe Dennis; John Attia; Elizabeth G Holliday; Mark McEvoy; Rodney J Scott; Katie Ashton; Tony Proietto; Geoffrey Otton; Mitul Shah; Shahana Ahmed; Catherine S Healey; Maggie Gorman; Lynn Martin; Shirley Hodgson; Peter A Fasching; Alexander Hein; Matthias W Beckmann; Arif B Ekici; Per Hall; Kamila Czene; Hatef Darabi; Jingmei Li; Matthias Dürst; Ingo Runnebaum; Peter Hillemanns; Thilo Dörk; Diether Lambrechts; Jeroen Depreeuw; Daniela Annibali; Frederic Amant; Hui Zhao; Ellen L Goode; Sean C Dowdy; Brooke L Fridley; Stacey J Winham; Helga B Salvesen; Tormund S Njølstad; Jone Trovik; Henrica M J Werner; Emma Tham; Tao Liu; Miriam Mints; Manjeet K Bolla; Kyriaki Michailidou; Jonathan P Tyrer; Qin Wang; John L Hopper; Julian Peto; Anthony J Swerdlow; Barbara Burwinkel; Hermann Brenner; Alfons Meindl; Hiltrud Brauch; Annika Lindblom; Jenny Chang-Claude; Fergus J Couch; Graham G Giles; Vessela N Kristensen; Angela Cox; Paul D P Pharoah; Alison M Dunning; Ian Tomlinson; Douglas F Easton; Deborah J Thompson; Amanda B Spurdle Journal: Endocr Relat Cancer Date: 2015-10 Impact factor: 5.678